ACG’s NEW VIRTUAL Functional GI Disorders School

In order to maximize effective online clinical education, ACG will be offering Functional GI Disorders School as a flexible combination of on-demand education supported by engaging LIVE Q&A with expert faculty. With ACG’s NEW VIRTUAL Functional GI Disorders School, you’ll receive on-demand access to over 8.75 hours of recorded lectures delivered by world-class faculty. Each of the 16 lectures will help you improve clinical judgment and address the art and science of Functional GI Disorders management. Videos will be available for viewing starting on Monday, November 23th. Watch the videos on your own time and have access to them for up to one year following the course.

Live Q&A Webcast Gives You Access to the Experts

Register by Saturday, December 5th and you will also receive exclusive access to three LIVE Q&A webcast sessions! Functional GI Disorders experts Dr. William D. Chey and Dr. Eamonn M. M. Quigley will host LIVE Q&A with the Functional GI Disorders School faculty on December 5th from 2:00 pm - 2:45 pm, 3:00 pm - 3:45 pm, and 4:00 pm - 4:45 pm (Eastern Time). Attendees will have the opportunity to submit questions in advance and during the live broadcasts. As an added resource, the recordings of the Q&A sessions will also be available to registrants following the sessions.

William D. Chey, MD, FACG
Course Co-Director
• Non-Medical Therapies for IBS: Soup to Nuts
• Microbiome-Based Treatments for IBS: Bugs or Drugs?
• Practice Pearl #3: The Inspired Digital Rectal Exam

Eamonn M. M. Quigley, MD, MACG
Course Co-Director
• Distinguishing Between Functional Dyspepsia and Gastroparesis: Does It Matter?
• Best of FGIDs in the AJG: 2019-2020

Lin Chang, MD, FACG
• What Does and What Does Not Cause IBS?
• The Chronically Constipated Patient: Avoiding Another Shutdown

Darren M. Brenner, MD, FACG
• Arriving at a Confident Diagnosis of IBS: Rule-Out or Rule-In?
• Medical Treatments for IBS: Sifting Through the Evidence

Douglas A. Drossman, MD, MACG
• Practice Pearl #2: Optimizing Patient-Provider Communication

Joan W. Chen, MD, MS
• Fecal Incontinence: Overflowing Options
• Practice Pearl #1: How to Teach Diaphragmatic Breathing

Stacy B. Menees, MD
• Diagnosis and Treatment of Functional Esophageal Disorders

Laurie A. Keefer, PhD
• Demystifying Behavioral Therapies for FGIDs: Connecting the Brain With the Gut
• Practice Pearl #1: How to Teach Diaphragmatic Breathing

Jen J. Shifferd, PT, CLT, WCS
• Practice Pearl #4: Physical Therapy for Patients With Pelvic Floor Disorders: A Primer for Gastroenterologists

PLUS! Access to Exclusive Live Q&A Sessions on Saturday, December 5, 2020

- December 5, 2:00 pm – 2:45 pm (Eastern Time)
  SESSION 1: UPPER GI DISORDERS
  Moderator: Eamonn M. M. Quigley, MD, MACG
  Laurie A. Keefer, PhD
  Joan W. Chen, MD, MS

- December 5, 3:00 pm – 3:45 pm (Eastern Time)
  SESSION 2: IRRITABLE BOWEL SYNDROME
  Moderator: William D. Chey, MD, FACG
  Lin Chang, MD, FACG
  Darren M. Brenner, MD, FACG
  Douglas A. Drossman, MD, MACG

- December 5, 4:00 pm – 4:45 pm (Eastern Time)
  SESSION 3: FGID POTPOURRI
  Moderator: Brian E. Lacy, MD, PhD, FACG
  Lin Chang, MD, FACG
  Stacy B. Menees, MD
  Jen J. Shifferd, PT, CLT, WCS
**SATELLITE SYMPOSIUM**

Saturday, December 5 • 5:45 pm (EDT)

**Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?**

Stephen A. Harrison, MD; Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF

**Program Overview**

Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate treatment. However, distinguishing NASH from other liver disorders and identifying high-risk patients remain challenging, and there are limited treatment options once a patient is diagnosed. While there are no approved medical therapies for NASH, multiple investigational agents have shown promise in late-stage trials and are expected to be available for NASH treatment soon.

This activity, Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know? will provide clinicians with the most current guidance on NASH diagnostic strategies. Clinician learners will also receive information on the efficacy, safety, and potential use of novel agents in late-stage clinical investigation for the treatment of patients with NASH.

**MORE INFO:** learning.rockpointe.com/a/CXGGVQ/contrib

**REGISTER:**

https://us02web.zoom.us/webinar/register/WN_ml21FC3MQnCQGAfAGAF